Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

NEXT STORY
Generex Biotechnology Announces Interview with President & CEO Joe Moscato
PREV STORY
Roche and Illumina partner to broaden patient access to genomic testing
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

author_avatar
NASDAQ Market News

Incysus Therapeutics Scientific Co-Founder Lawrence Lamb, PhD to Present at 8th International Gamma-Delta T Cell Conference

Symposium Title: “Targeting of chemotherapy-induced NKG2DL by localized repetitive γδ T cell infusions: a ...

author_avatar
NASDAQ Market News

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

author_avatar
NASDAQ Market News